{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:38:22Z","timestamp":1761896302799},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.diabres.2016.03.015","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T10:02:07Z","timestamp":1462788127000},"page":"127-135","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy"],"prefix":"10.1016","volume":"116","author":[{"given":"Peter","family":"Bramlage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Bluhmki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Rathmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kaltheuner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Beyersmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Danne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.diabres.2016.03.015_b0005","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.diabres.2016.03.015_b0010","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group","volume":"44","author":"U.K. prospective diabetes study 16","year":"1995","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.diabres.2016.03.015_b0015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2016.03.015_b0020","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/dc13-2743","article-title":"Insulin therapy in people with type 2 diabetes: opportunities and challenges?","volume":"37","author":"Home","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2016.03.015_b0025","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1055\/s-0029-1239559","article-title":"Medical antihyperglycemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association","volume":"117","author":"Matthaei","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"Suppl. 2","key":"10.1016\/j.diabres.2016.03.015_b0030","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.2337\/dc09-S319","article-title":"Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond","volume":"32","author":"Bretzel","year":"2009","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2016.03.015_b0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","article-title":"Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride","volume":"37","author":"Eliaschewitz","year":"2006","journal-title":"Arch Med Res"},{"issue":"12","key":"10.1016\/j.diabres.2016.03.015_b0040","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial","volume":"138","author":"Fritsche","year":"2003","journal-title":"Ann Intern Med"},{"issue":"Suppl.","key":"10.1016\/j.diabres.2016.03.015_b0045","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/0168-8227(95)01077-Q","article-title":"Insulin therapy in type II diabetes","volume":"28","author":"Holman","year":"1995","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2016.03.015_b0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00000441-200607000-00005","article-title":"Basal-prandial insulin therapy: scientific concept review and application","volume":"332","author":"Leahy","year":"2006","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.diabres.2016.03.015_b0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"9131","key":"10.1016\/j.diabres.2016.03.015_b0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2016.03.015_b0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/dc09-1348","article-title":"Correlates of insulin injection omission","volume":"33","author":"Peyrot","year":"2010","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2016.03.015_b0070","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1185\/030079907X242638","article-title":"Barriers to the initiation of, and persistence with, insulin therapy","volume":"23","author":"Oliveria","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"18","key":"10.1016\/j.diabres.2016.03.015_b0075","first-page":"934","article-title":"\u201cDIabetes Versorgungs-Evaluation\u201d (DIVE) \u2013 a national quality assurance initiative at physicians providing care for patients with diabetes","volume":"138","author":"Danne","year":"2013","journal-title":"Dtsch Med Wochenschr"},{"issue":"1","key":"10.1016\/j.diabres.2016.03.015_b0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1373\/clinchem.2003.024802","article-title":"IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study","volume":"50","author":"Hoelzel","year":"2004","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.diabres.2016.03.015_b0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"10.1016\/j.diabres.2016.03.015_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i02","article-title":"Multiple Imputation with Diagnostics (mi) in R: opening Windows into the Black Box","volume":"45","author":"Su","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.diabres.2016.03.015_b0095","author":"Lumley"},{"key":"10.1016\/j.diabres.2016.03.015_b0100","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"issue":"11","key":"10.1016\/j.diabres.2016.03.015_b0105","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1463-1326.2011.01433.x","article-title":"Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis","volume":"13","author":"Pontiroli","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2016.03.015_b0110","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.2337\/dc13-3010","article-title":"Factors associated with weight gain in people with type 2 diabetes starting on insulin","volume":"37","author":"Balkau","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2016.03.015_b0115","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/diacare.27.5.1218","article-title":"A systematic review of adherence with medications for diabetes","volume":"27","author":"Cramer","year":"2004","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.diabres.2016.03.015_b0120","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"7618","key":"10.1016\/j.diabres.2016.03.015_b0125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/bmj.39314.620174.80","article-title":"Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review","volume":"335","author":"Eurich","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.diabres.2016.03.015_b0130","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diacare.23.5.644","article-title":"Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo","volume":"23","author":"Heinemann","year":"2000","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2016.03.015_b0135","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-Jarvinen","year":"2006","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.diabres.2016.03.015_b0140","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1177\/193229681300700527","article-title":"Different injection frequencies of basal insulins in type 2 diabetes patients under real-life conditions: a retrospective database analysis","volume":"7","author":"Rathmann","year":"2013","journal-title":"J Diabetes Sci Technol"},{"issue":"11","key":"10.1016\/j.diabres.2016.03.015_b0145","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.03.015_b0150","series-title":"Competing risks and multistate models with R","author":"Beyersmann","year":"2012"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716300407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716300407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T02:22:45Z","timestamp":1536718965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716300407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":30,"alternative-id":["S0168822716300407"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2016.03.015","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2016.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}